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Objective. To develop criteria for the classification
of macrophage activation syndrome (MAS) in patients
with systemic juvenile idiopathic arthritis (JIA).
Methods. A multistep process, based on a combi-
nation of expert consensus and analysis of real patient
data, was conducted. A panel of 28 experts was first
asked to classify 428 patient profiles as having or not
having MAS, based on clinical and laboratory features
at the time of disease onset. The 428 profiles comprised
161 patients with systemic JIA–associated MAS and
267 patients with a condition that could potentially be
confused with MAS (active systemic JIA without evi-
dence of MAS, or systemic infection). Next, the ability
of candidate criteria to classify individual patients as
having MAS or not having MAS was assessed by evalu-
ating the agreement between the classification yielded
using the criteria and the consensus classification of
the experts. The final criteria were selected in a consen-
sus conference.
Results. Experts achieved consensus on the clas-
sification of 391 of the 428 patient profiles (91.4%).
A total of 982 candidate criteria were tested statistically.
The 37 best-performing criteria and 8 criteria obtained
from the literature were evaluated at the consensus con-
ference. During the conference, 82% consensus among
experts was reached on the final MAS classification cri-
teria. In validation analyses, these criteria had a sensitiv-
ity of 0.73 and a specificity of 0.99. Agreement between
the classification (MAS or not MAS) obtained using the
criteria and the original diagnosis made by the treating
physician was high (k5 0.76).
Conclusion. We have developed a set of classifi-
cation criteria for MAS complicating systemic JIA and
provided preliminary evidence of its validity. Use of
these criteria will potentially improve understanding of
MAS in systemic JIA and enhance efforts to discover
effective therapies, by ensuring appropriate patient
enrollment in studies.
Introduction
Macrophage activation syndrome (MAS) is the
term used to describe a potentially life-threatening com-
plication of systemic inflammatory disorders, which
occurs most commonly in systemic juvenile idiopathic
arthritis (JIA) and in its adult equivalent, adult-onset
Still’s disease (1–4), although its occurrence in patients
with other autoimmune or autoinflammatory condi-
tions, i.e., adult- and childhood-onset systemic lupus
erythematosus (5,6), Kawasaki disease (7,8), and peri-
odic fever syndromes (9,10), is being reported with
increased frequency. MAS is characterized by an over-
whelming inflammatory reaction due to an uncontrolled
and dysfunctional immune response involving the con-
tinual activation and expansion of T lymphocytes and
macrophages, which results in massive hypersecretion of
proinflammatory cytokines (11,12).
Characteristic clinical features of MAS are high,
nonremitting fever, hepatosplenomegaly, generalized
lymphadenopathy, central nervous system dysfunction,
and hemorrhagic manifestations. Typical laboratory
abnormalities include pancytopenia, increased levels of
ferritin, liver enzymes, lactate dehydrogenase, triglycer-
ides, D-dimers, and soluble interleukin-2 (IL-2) receptor
a (also known as soluble CD25 [sCD25]), and decreased
fibrinogen levels. A typical histopathologic feature of
MAS is the accumulation of well-differentiated macro-
phages exhibiting hemophagocytic activity in bone
marrow biopsy specimens or aspirates (13). Although the
prevalence of MAS among patients with systemic JIA has
been estimated to be ;10%, recent reports suggest that
subclinical MAS may occur in as many as 30-40% of
patients with systemic JIA (14,15).
MAS can result in progressive multi-organ failure
and eventually a fatal outcome if unrecognized. Recent
studies indicate a mortality rate of 8% (16,17), making
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timely diagnosis and prompt initiation of appropriate treat-
ment imperative. However, early recognition of MAS is
often challenging, given the lack of a single pathognomonic
clinical or laboratory feature. Furthermore, histopathologic
features of hemophagocytosis may not be present in the
initial stages (18,19) and lack specificity for hemophago-
cytic syndromes (20). In addition, features of MAS may be
difficult to distinguish from other conditions that may pre-
sent with overlapping manifestations, such as flares of sys-
temic JIA or systemic infections. Recently, a wide disparity
in the frequency and severity of the classic clinical and lab-
oratory features across patients has been described (16,17).
The difficulties in making the diagnosis of MAS
and its clinical heterogeneity, together with the recent
advances in its treatment and in understanding of its path-
ophysiology and underlying genetic defects (11,21–23),
emphasize the need for accurate criteria to aid physicians
in appropriately classifying patients as having MAS to
facilitate enrollment into clinical studies. The recognition
that the syndrome is clinically similar to hemophagocytic
lymphohistiocytosis (HLH) has led some to recommend
the use of the HLH-2004 diagnostic guidelines (24). An
alternative approach is based on application of the prelim-
inary diagnostic guidelines for MAS complicating systemic
JIA (25). However, although both sets of guidelines have
been utilized for detecting MAS in patients with systemic
JIA, each has several limitations (26). The primary pur-
pose of the international collaborative project described
herein, conducted under the auspices of the European
League Against Rheumatism, the American College of
Rheumatology, and the Paediatric Rheumatology Interna-
tional Trials Organisation (PRINTO), was to develop a set
of classification criteria for MAS complicating systemic
JIA, based on a combination of expert consensus, available
evidence from the medical literature, and analysis of real
patient data.
Methods
A multistep process was used in developing the classi-
fication criteria and included the following phases: 1) a Delphi
survey of international pediatric rheumatologists, aimed at
identifying MAS features potentially suitable for inclusion in
classification criteria (27); 2) large-scale data collection on
patients with systemic JIA–associated MAS and patients with
2 other conditions that potentially could be confused with
MAS; 3) a web-based procedure for ascertaining consensus
among experts; 4) selection of candidate criteria through statis-
tical analyses; 5) selection of final classification criteria in a con-
sensus conference; and 6) cross-sectional validation of final
classification criteria. Health professionals and patient/parent
representatives were not included in the study task force
because the project did not involve any issues of specific interest
to these stakeholders. In particular, none of the study assess-
ments required the participation of health professionals, and no
patient/parent-reported outcomes were incorporated.
Data collection on patients with MAS and patients
with conditions that could be confused with MAS. The design,
inclusion criteria, and data collection procedures of this por-
tion of the project have been described in detail previously
(16,17,26). Briefly, international pediatric rheumatologists and
pediatric hematologists were invited to participate in a retro-
spective cohort study of patients with systemic JIA–associated
MAS or with 1 of 2 conditions that could potentially be
confused with MAS, i.e., active systemic JIA not complicated
by MAS and systemic infection.
For patients with MAS, information on laboratory fea-
tures at 3 time points (the last visit before onset of MAS, the
time of MAS onset, and the period of full-blown MAS) was
collected. Because the classification criteria were aimed at
identification of MAS in its earlier stages, only laboratory data
recorded at the time of onset were retained. Data at the time
of presentation in patients with conditions that could be con-
fused with MAS were also obtained. Except for blood cell
counts and acute-phase reactant levels, values of laboratory
parameters were tested using both the original values provided
by each local laboratory and the values standardized according
to the SI unit system based on their normal ranges, as previ-
ously reported (16).
A total of 1,111 patients (362 with systemic JIA–associated
MAS, 404 with active systemic JIA without MAS, and 345 with
systemic infection) were reported by 95 pediatric subspecialists
practicing in 33 countries in 6 continents. Pediatric subspecialists
who provided these data are listed in Appendix A. The features of
the patients with MAS and the comparison patients have been
described elsewhere (16,17,26).
Web-based procedures for ascertaining consensus
among experts. At present, there is no single feature that is
pathognomonic for MAS. Furthermore, no prior validated
diagnostic or classification criteria are available. In order to
classify patients as having or not having MAS, we therefore
decided to use expert consensus as the “gold standard.” Based
on publication records and experience in the care of children
with MAS and related disorders, a panel of 28 experts (20
pediatric rheumatologists and 8 pediatric hematologists) was
created.
The experts were asked to classify a total of 428 patient
profiles as having or not having MAS, based on the clinical and
laboratory features recorded at disease onset. The 428 profiles
were selected randomly from among the 1,111 patients whose
data were collected and comprised 161 patients with MAS, 140
patients with active systemic JIA without evidence of MAS, and
127 patients with systemic infection. Selection bias was unlikely,
as the characteristics of patients who were selected and those
who were not selected were comparable (data not shown). The
experts were intentionally kept unaware of the original diagnosis
and overall course of each patient.
Each patient profile included information about the
presence or absence of key clinical manifestations, and the val-
ues of laboratory parameters and normal ranges at the respec-
tive institutions. Based on these data, all experts were asked to
classify each patient as having or not having MAS. The mini-
mum required level of agreement among experts was set at
80%. If an 80% consensus was not attained, the patient profile
was discussed in a further round. Profiles for which consensus
had not been achieved after the final round were declared
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uninterpretable and discarded from further analyses. Three
rounds of voting were used, with prior vote data and recorded
comments available to all of the participants before each vote
took place, to augment the number of consensus decisions. All
web-based consensus procedures were conducted by PRINTO.
Selection of best classification criteria through sta-
tistical analyses. All statistical analyses used for selecting the
best classification criteria were conducted only on the sample
of patients for whom the experts achieved consensus about the
diagnosis of MAS or non-MAS. Cutoff values for laboratory
tests were calculated with the receiver operator characteristic
(ROC) curve method, by identifying the point on the ROC
curve that best discriminated between patients classified by the
experts as having MAS and those classified as not having MAS.
The aim of this exercise was to assess the ability of can-
didate criteria to classify individual patients as having or not
having MAS, and to evaluate the agreement between the classi-
fication yielded by the criteria and the consensus classification
of experts. Candidate classification criteria were partly derived
from the literature and partly generated from the study data.
Literature criteria included the following: 1) the pre-
liminary diagnostic guidelines for MAS complicating systemic
JIA (25), 2) the same guidelines modified by addition of the
item ferritin at various threshold levels (500, 1,000 or 1,500
ng/ml), and 3) the HLH-2004 diagnostic guidelines (24),
adapted by eliminating 3 of the 8 items because information
about presence of hemophagocytosis was not available for
both comparison groups, and neither natural killer (NK) cell
activity nor sCD25 levels were determined in all patients.
Criteria obtained from the study data were generated in 2
ways: 1) through the evaluation, by the project steering com-
mittee, of all combinations of clinical and laboratory variables
(see some examples in Supplementary Table 1, on the Arthritis
& Rheumatology web site at http://onlinelibrary.wiley.com/doi/
10.1002/art.39332/abstract) (combination of criteria approach),
and 2) by assigning weights to clinical and laboratory variables,
on the basis of their association with the diagnosis of MAS
made by the experts, through multivariable logistic regression
analysis. For each combination of variables that were signifi-
cantly associated with the diagnosis of MAS in logistic regres-
sion models, the rule was to convert the odds ratio of each
variable to its percentage value out of a total of 100%. Each set
of criteria was then composed of a group of variables whose
sum of weights made up a total score of 100 (MAS score). The
cutoff value in the MAS score that was associated with the
higher likelihood of the presence of MAS was obtained by cal-
culating the point on the ROC curve that corresponded to the
highest sensitivity and specificity.
A total of 982 candidate classification criteria were
tested. For each set of criteria, we calculated the sensitivity
(ability of the criteria to identify a patient as having MAS who
had been classified as having MAS according to the expert
panel), the specificity (ability of the criteria to identify a
patient as not having MAS who had been classified as not hav-
ing MAS by the experts), the positive and negative predictive
value, the area under the ROC curve (AUC), and the kappa
value for agreement between the classification yielded by the
criteria and the classification made by the experts. Although
Figure 1. Patient samples evaluated in the study and results of web-based expert evaluations. MAS5macrophage activation syndrome;
sJIA5 systemic juvenile idiopathic arthritis.
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there was one single model with the highest predictive value
(criterion no. 929; Supplementary Table 1), we generated mul-
tiple combinations for comparison because we believed that
less predictive models might have more face validity with the
experts. Nevertheless, it was established that in order to quali-
fy for inclusion in expert voting procedures at the consensus
conference, a set of classification criteria should demonstrate
a kappa value of $0.85, a sensitivity of $0.80, a specificity
of $0.93, and an AUC of $0.90. An exception was made for
the historical literature criteria, which were retained for fur-
ther consideration even if they did not meet all statistical
requirements.
Selection of the final classification criteria at consen-
sus conference. The International Consensus Conference on
MAS Classification Criteria was held in Genoa, Italy on
March 21–22, 2014. The meeting was attended by all 28
experts who participated in web-based consensus evaluations
and was facilitated by 2 moderators (HIB and NR) with
expertise in nominal group technique. The overall goal of the
meeting was to decide on a preliminary set of classification
criteria using a combination of statistical and consensus for-
mation techniques.
A plenary session was first held to present the scope,
methodology, and flow of the project, the results of the Delphi
survey, the characteristics of patients included in the data col-
lection, the results of web-based consensus procedures and of
statistical analyses of candidate classification criteria, and the
methodology of the nominal group technique. Participants
were then randomized into 2 equal-sized nominal groups and
were asked to rank using nominal group technique, indepen-
dently of each other and based on the evaluation of both ease
of use and credibility (face/content validity) and statistical per-
formance (particularly in terms of sensitivity, specificity, and
kappa value), the 5 best classification criteria from 5 (highest)
to 1 (lowest). All experts were connected by their laptops to a
central computer and submitted all of their rankings electroni-
cally. A series of repeated independent voting sessions was
held until the top 3 classification criteria were selected by each
voting group. Then an 80% consensus was attained on the best
(final) set of classification criteria, in a session with members
of the 2 nominal groups combined.
Analysis of the association between the variables includ-
ed in the final classification criteria and the web-based experts’
consensus evaluations. The association between the final clas-
sification criteria and the web-based evaluations made by the
experts was assessed by multiple logistic regression analysis,
which used as explanatory variables the individual items
included in the final classification criteria and as the depen-
dent variable the web-based expert consensus on classification
of patients as having or not having MAS. The effect was
expressed in terms of odds ratios, and 95% confidence inter-
vals were calculated; statistical significance was tested by likeli-
Table 1. Comparison of clinical and laboratory features at disease onset between patients classified by the 28-member expert panel as having
macrophage activation syndrome (MAS) (n5 95) and those classified as not having MAS (n5 296)
Patients classified as
having MAS
Patients classified as
not having MAS
P
No. with
available
data
No. (%) or
median (IQR)*
No. with
available
data
No. (%) or
median (IQR)*
Clinical manifestations
Fever 94 93 (98.9) 294 278 (94.6) 0.08
Hepatomegaly 94 68 (72.3) 295 75 (25.4) ,0.0001
Splenomegaly 92 53 (57.6) 294 67 (22.8) ,0.0001
Lymphadenopathy 91 48 (52.8) 292 73 (25.0) ,0.0001
Central nervous system involvement 93 40 (43.0) 292 25 (8.6) ,0.0001
Hemorrhagic manifestations 92 25 (27.2) 294 16 (5.4) ,0.0001
Heart involvement 94 27 (28.7) 294 34 (11.6) ,0.0001
Lung involvement 95 27 (28.4) 294 40 (13.6) 0.0009
Kidney involvement 95 16 (16.8) 295 16 (5.4) 0.0004
Laboratory results
Hemoglobin, gm/dl 95 9.9 (8.0–11.2) 289 10.9 (9.4–12.2) ,0.0001
White blood cell count, 3109/liter 95 8.1 (3.2–12.8) 289 15.3 (9.9–20.1) ,0.0001
Neutrophil count, 3109/liter 82 3.7 (1.5–8.0) 236 9.4 (5.1–14.2) ,0.0001
Platelet count, 3109/liter 95 98 (57–141) 290 385 (286–551) ,0.0001
Erythrocyte sedimentation rate, mm/hour 90 28 (17–65) 245 70 (39–93) ,0.0001
C-reactive protein, mg/dl 85 8.7 (2.4–16.1) 282 8.2 (2.4–15.6) 0.63
Aspartate aminotransferase, units/liter 93 171 (98–436) 284 30 (22–45) ,0.0001
Alanine aminotransferase, units/liter 91 115 (43–283) 284 18 (12–34) ,0.0001
Lactate dehydrogenase, units/liter 81 1,560 (801–2,400) 248 482 (362–688) ,0.0001
Triglycerides, mg/dl 86 267 (192–358) 186 123 (96–160) ,0.0001
Albumin, gm/dl 79 3.0 (2.6–3.5) 252 3.7 (3.2–4.1) ,0.0001
Serum sodium, mEq/liter 80 136 (133–140) 259 138 (136–141) 0.003
Fibrinogen, mg/dl 88 220 (148–345) 226 500 (356–650) ,0.0001
Ferritin, ng/ml 90 9,094 (2,000–19,767) 244 268 (62–938) ,0.0001
D-dimer, ng/ml 48 3,579 (1,834–7,373) 94 1,638 (528–3,325) ,0.0001
* Clinical manifestations are reported as the number (%) and laboratory results as the median (interquartile range [IQR]).
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hood ratio test. The AUC of the model was used as an indica-
tor of its predictive ability. The purpose of this post-consensus
analysis was to evaluate which were the variables that most
influenced the experts’ decision to classify the patients as hav-
ing or not having MAS.
Validation of final classification criteria. Validation ana-
lysis was performed by assessing the performance of the criteria,
in terms of sensitivity, specificity, negative predictive value, posi-
tive predictive value, AUC, and kappa value, in discriminating
patients with MAS from patients with the 2 conditions with
which MAS could be confused (combined in a single group),
using the original diagnosis made by the caring physician (i.e.,
the investigator who entered the patient’s data in the study web
site) as the gold standard. This analysis was performed on the
sample of patients not used for expert evaluations (n5 683).
Only patients with available data on all items included in the
final classification criteria were used for the analyses.
Results
Results of web-based process for ascertainment
of expert consensus. After 3 rounds of web-based evalua-
tions, the experts achieved consensus on the classification
of 391 (91.4%) of the 428 patient profiles examined (Fig-
ure 1). A total of 95 patients were classified as having MAS
by the experts, 88 of whom had also been diagnosed as hav-
ing MAS by the treating physician; the original diagnosis
had been systemic JIA without MAS in 3 patients and sys-
temic infection in 4. A total of 296 patients were classified
by the experts as not having MAS, 47 of whom had been
diagnosed as having MAS by the treating physician. Thirty-
seven patient profiles for which 80% consensus among
experts was not reached were discarded. A comparison of
Table 2. Univariate analysis of the ability of specific variables to distinguish patients with macrophage acti-
vation syndrome from comparison patients, as assessed using the 391 patients for whom expert consensus was
achieved
No. of patients
with available
data OR (95% CI)* P
Clinical features
Central nervous system involvement 385 8.1 (4.5–14.4) ,0.0001
Hepatomegaly 389 7.7 (4.5–12.9) ,0.0001
Hemorrhagic manifestations 386 6.5 (3.3–12.8) ,0.0001
Fever 388 5.4 (0.7–40.9) 0.106
Splenomegaly 386 4.6 (2.8–7.6) ,0.0001
Lymphoadenopathy 383 3.4 (2.1–5.5) ,0.0001
Kidney involvement 390 3.5 (1.7–7.4) 0.0008
Heart involvement 388 3.1 (1.7–5.5) 0.0001
Lung involvement 389 2.5 (1.4–4.4) 0.0011
Active arthritis 390 1.6 (1.0–2.6) 0.0587
Laboratory features
Non-normalized values
Ferritin .684 ng/ml 334 111.6 (26.7–465.8) ,0.0001
Platelet count #181 3 109/liter 385 84.3 (40–177.5) ,0.0001
Aspartate aminotransferase .48 units/liter 377 51.9 (21.7–124.4) ,0.0001
Lactate dehydrogenase .853 units/liter 329 20.0 (10.7–37.3) ,0.0001
Triglycerides .156 mg/dl 272 19.6 (9.4–40.8) ,0.0001
Alanine aminotransferase .36 units/liter 375 18.0 (9.4–34.3) ,0.0001
Fibrinogen #360 mg/dl 314 11.5 (6.3–21.0) ,0.0001
Neutrophil count #3.7 3 109/liter 318 5.9 (3.4–10.5) ,0.0001
D-dimer .1,350 ng/ml 142 5.7 (2.4–13.4) ,0.0001
Erythrocyte sedimentation rate #30 mm/hour 335 5.6 (3.3–9.5) ,0.0001
Albumin #3.6 gm/dl 331 5.5 (3.0–10.1) ,0.0001
Hemoglobin #8.5 gm/dl 384 4.9 (2.7–8.8) ,0.0001
White blood cell count #10.2 3 109/liter 384 4.6 (2.8–7.5) ,0.0001
Serum sodium #133, mEq/liter 339 2.9 (1.7–5.0) 0.0002
C-reactive protein .0.86 mg/dl 367 2.4 (1.0–5.9) 0.0501
Normalized values
Ferritin .2,773.6 ng/ml 334 23.9 (12.7–44.8) ,0.0001
Aspartate aminotransferase .44.4 units/liter 377 47.4 (21.6–103.9) ,0.0001
Alanine aminotransferase .23 units/liter 375 39.4 (14.1–110.5) ,0.0001
Lactate dehydrogenase .238.8 units/liter 329 39.2 (18.2–84.6) ,0.0001
Triglycerides .193.9 mg/dl 272 16.3 (8.7–30.8) ,0.0001
Fibrinogen #318.9 mg/dl 314 11.0 (6.1–20.0) ,0.0001
Albumin #3.9 gm/dl 331 6.4 (3.6–11.3) ,0.0001
D-dimer .1,320.3 ng/ml 142 5.2 (2.1–12.7) ,0.0001
Serum sodium #135 mEq/liter 339 3.3 (1.9–5.6) ,0.0001
* OR5 odds ratio; 95% CI5 95% confidence interval.
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clinical and laboratory features between patients diagnosed
by the experts as having MAS and those diagnosed as not
having MAS is shown in Table 1. Overall, patients whose
condition was classified as MAS by the experts had more
severe clinical and laboratory features than those classified
as not having MAS.
Candidate clinical and laboratory variables
determined by univariate analysis. In univariate analy-
ses, the 10 variables found to have the greatest ability to dis-
tinguish patients with MAS from comparison patients were
as follows: ferritin level, platelet count, levels of aspartate
transaminase (AST), lactate dehydrogenase, triglycerides,
alanine transaminase (ALT), and fibrinogen, central ner-
vous system involvement, hepatomegaly, and hemorrhagic
manifestations (Table 2). These variables qualified for inclu-
sion in logistic regression analyses aimed at generating can-
didate classification criteria through the MAS score method
described above. However, ALT levels were excluded owing
to their close correlation with AST levels and a slightly lower
statistical performance. They were replaced by neutrophil
count or albumin level, depending on the model.
Candidate classification criteria sets. Of the
982 sets of criteria tested, 45 were retained for further
evaluation at the consensus conference. Of these, 37 (20
generated through the combination of criteria approach
and 17 obtained with the MAS score method) were rep-
resented by criteria that met the statistical requirements
described in Methods, and 8 were criteria derived from
the literature. The statistical performance of the 20 best
candidate criteria is presented in Supplementary Table
1 (on the Arthritis & Rheumatology web site at http://
onlinelibrary.wiley.com/doi/10.1002/art.39332/abstract).
The definition of and statistics on all 982 criteria tested are
available from the corresponding author upon request.
Final classification criteria selected at face-to-
face conference. During the consensus conference, 7
voting sessions were held among the 28 experts until 3
top classification criteria sets remained (criteria nos. 466,
472, and 929; Supplementary Table 1). Notably, the same
criteria were selected independently by the 2 nominal
groups, confirming convergent validity of the selection
process. After the last voting session, 82% consensus was
reached on the final definition (criteria no. 472; Supple-
mentary Table 1). A subsequent open face-to-face discus-
sion among all experts led to the decision to include in
the final definition the presence of fever as a mandatory
criterion and the requirement that the patient should
have known or suspected systemic JIA. The final classifi-
cation criteria selected at the consensus conference are
presented in Figure 2.
Association between final classification criteria
and experts’ web-based consensus evaluations. For
this multivariable analysis, complete data were available
on 227 patients. The logistic regression model to evaluate
Figure 2. Criteria for the classification of macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. Laboratory abnor-
malities should not be otherwise explained by the patient’s condition, such as concomitant immune-mediated thrombocytopenia, infectious hepatitis,
visceral leishmaniasis, or familial hyperlipidemia.
Table 3. Logistic regression model to assess association between
the variables included in the final classification criteria and the
experts’ consensus of patients’ classification as having or not having
macrophage activation syndrome*
Explanatory variable OR (95% CI) P†
Ferritin .684 ng/ml .999.999 (40.62.999.999) ,0.0001
Platelet count
#181 3 109/liter
237.0 (18.22.999.999) ,0.0001
Triglycerides .156 mg/dl 18.3 (2.0–163.9) 0.009
Fibrinogen #360 mg/dl 16.0 (2.0–126.4) 0.009
Aspartate aminotransferase
.48 units/liter
10.0 (1.3–78.4) 0.029
* The experts’ consensus on patients’ classification as having or not
having macrophage activation syndrome (from the web-based pro-
cess) was the dependent variable. Complete data were available on
227 patients. The area under the receiver operating characteristic
curve of the model was 0.99. OR5 odds ratio; 95% CI5 95% confi-
dence interval.
† By likelihood ratio test.
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which were the variables included in the final classifica-
tion criteria that most influenced the experts’ decision
to classify a patient as having or not having MAS is
presented in Table 3. All variables were independently
correlated with the experts’ diagnoses. However, the
association was much stronger for ferritin and platelet
count. The AUC of the model was 0.99.
Preliminary validation of the final criteria set. The
evaluation of the ability of the new classification criteria to
discriminate MAS from comparator conditions in the
patient sample not included in the expert evaluations
(n5 415 of 683) showed a sensitivity of 0.73, a specificity of
0.99, a positive predictive value of 97.4%, a negative predic-
tive value of 85.9%, an AUC of 0.86, and a kappa value for
agreement between the diagnosis yielded by the criteria and
the diagnosis made by the treating physician of 0.76.
Discussion
Using a consensus process as well as a statistical
approach, we have developed a new set of classification
criteria for MAS complicating systemic JIA (Figure 2).
Because the criteria were established against compari-
son samples composed of patients with either a rheuma-
tologic condition (active systemic JIA without evidence
of MAS) or a nonrheumatologic condition (systemic
infection), they may be of interest to a specialists in a
range of disciplines.
The classification criteria include only laboratory
variables and no clinical manifestations, with the exception
of fever. This choice is in accordance with the common
view that suspicion of MAS is most commonly raised by
detection of subtle laboratory alterations, whereas clinical
symptoms are often delayed and/or similar to those
observed in other conditions (28). In a previous analysis of
the MAS sample included in the present study, we found
that 4 of the 5 laboratory tests that are part of the criteria
(ferritin, platelet count, AST, and triglycerides) were
among the parameters that showed a change of .50%
between the last visit before the onset of MAS and the
onset of MAS (16). In the same study, ferritin levels exhib-
ited the largest change over time, which underscores the
major importance of this feature in MAS detection and
supports its use as a mandatory criterion. The key value of
ferritin in the classification of MAS was corroborated by
the observation that it was the parameter that had the
greatest influence on the experts’ classification of patients
as having or not having MAS (Table 3).
Although the presence of fever did not enable
discrimination between MAS and comparator illnesses
as it was found in all or nearly all patients in each sam-
ple, the expert panel considered fever a prerequisite for
the classification of MAS. The cardinal diagnostic role
of fever is substantiated by the observation that it was
the mostly highly ranked clinical feature identified in
the Delphi survey (27). Unfortunately, we lacked reli-
able information on the pattern of fever in the 3 patient
groups. However, it is generally accepted that the onset
of MAS is heralded by a shift from the high-spiking
intermittent pattern typical of active systemic JIA to a
continuous nonremitting pattern (3,4,29).
The detection of macrophage hemophagocytosis
in bone marrow biopsy specimens or aspirates or reticu-
loendothelial organ biopsy specimens is another frequent
and characteristic feature of MAS. However, because
hemophagocytosis is often absent during the early stages
of MAS (18,19) and its demonstration requires an inva-
sive procedure, the expert panel deemed it not necessary
for the classification of systemic JIA–associated MAS.
Notably, the demonstration of hemophagocytosis is not
mandatory in either the HLH-2004 or the preliminary
MAS diagnostic guidelines (24,25).
Although possibly useful for diagnostic purposes,
the classification criteria are primarily intended for use in
clinical trials and research studies. The criteria exhibited
high accuracy and face/content validity in consensus and
statistical evaluations, but it should be taken into account
that they were developed using expert consensus as the
gold standard. It also should be noted that the experts
were asked to differentiate MAS from non-MAS condi-
tions by reviewing the clinical features and laboratory val-
ues recorded at a single point in time (i.e., at disease
onset), and were unaware of the patient’s clinical course,
laboratory values over time, response to treatment, or
outcome. This information was, however, available to the
treating physician, who made the original diagnosis in the
clinical setting. This disparity in the available information
may partially explain the high proportion of patients who
were diagnosed by the treating physician as having MAS
but classified by the experts as not having MAS (47 of
161; 29.2%). It is conceivable that because the experts
were provided with only the information relevant to the
development of the criteria, they tended to confirm the
diagnosis of MAS only in straightforward and unambigu-
ous cases.
It is therefore important to emphasize that the clas-
sification criteria may not capture all instances of MAS
seen in the routine clinical setting, particularly those with
subtle onset or incomplete clinical expression. Notably, of
the 47 patients for whom the treating physician’s diagnosis
of MAS was not confirmed by the experts, 30 (63.8%) also
did not meet the final classification criteria, 11 (23.4%)
could not be assessed due to lack of data on the laboratory
variables needed to apply the criteria, and only 6 (12.8%)
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were classified as having MAS according to the final classi-
fication criteria. In addition, only 18 (46.6%) of the 37
patients for whom the experts could not agree on the diag-
nosis were classified as having MAS according to the final
classification criteria. These findings underscore the con-
sistency of the experts’ evaluations and support the validity
of the final classification criteria.
The fact that the cutoff values for platelet count
and fibrinogen level included in the criteria are within the
normal range of routine laboratory assessments may be
regarded as clinically implausible. The same may apply to
the cutoffs for AST and triglycerides, which are only
slightly above the upper limits of normal. However, it is
widely recognized that children with active systemic JIA
often have increased platelet counts (e.g., .6002 800 3
109/liter) as well as elevated fibrinogen levels (e.g., .500–
600 mg/dl) as part of the underlying inflammatory process
(30,31). Thus, a paradoxically normal platelet count or
fibrinogen level in the setting of otherwise prominent sys-
temic inflammation may raise the suspicion of MAS
(16,28). Because the levels of serum transaminases and
triglycerides are generally normal in children with system-
ic JIA who do not have other coexistent pathologic condi-
tions (e.g., infectious hepatitis or familial hyperlipidemia),
their simple increase above the upper normal limits, com-
bined with the other clinical and laboratory parameters
included in the criteria, may be sufficient to herald the
occurrence of MAS. This fits with the real-world patient
data used in these studies to establish cutoff values that
distinguish between children with JIA who have MAS
and those who do not have MAS.
A secondary objective of the present project was
analysis of the role of change in laboratory findings
over time in the detection of MAS. However, this exer-
cise was performed only for descriptive purposes, i.e.,
to identify and rank the laboratory parameters for
which change over time was deemed by the experts as
most important or useful for early detection of MAS.
Because serial laboratory results were available for
patients with MAS but not for the comparator groups,
we could not establish the threshold level of change in
each parameter that had the greatest sensitivity and
specificity for the diagnosis of MAS. This precluded
the ability to incorporate the change in laboratory
values over time in the classification criteria. Due to
space constraints, this analysis is reported in a separate
manuscript (32).
Recently there have been several reports, from
randomized controlled clinical trials and from postmar-
keting experience, of MAS occurring in patients with
systemic JIA being treated with the cytokine blockers
canakinumab and tocilizumab (33–35). Because these
agents inhibit the biologic effects of IL-1 and IL-6,
respectively, which are among the proinflammatory
cytokines involved in the physiopathology of MAS
(11,36), it is conceivable that MAS episodes developing
during treatment with these biologic agents may occur
in the absence of fever or some of the typical laboratory
abnormalities of the syndrome. Clinical symptoms in
patients with systemic JIA–associated MAS receiving
tocilizumab were found to be milder than those in
patients not receiving this treatment (37). Preliminary
analyses in patients who developed MAS while receiving
tocilizumab or canakinumab have shown that a few
cases did not meet the new criteria, due to the absence
of fever or a peak ferritin level of ,684 ng/ml (38,39).
More data from real-world clinical practice are needed
to establish whether the criteria should be refined to
increase their power to identify MAS occurring during
treatment with IL-1 and IL-6 inhibitors.
Our study should be interpreted in light of
some potential caveats. Patient data were collected
through retrospective review of clinical charts, and ret-
rospective analysis is subject to missing and possibly
erroneous data. However, because all patient profiles
were reviewed by the experts and the diagnosis of
MAS or non-MAS was confirmed only when a high
level of consensus was reached, the impact of this
potential limitation was likely minimized. Some
important diagnostic parameters of MAS, such as
sCD25 and sCD163 levels and NK cell activity, could
not be assessed due to their unavailability in some of
the patient samples. However, these biomarkers are
not routinely assessed, nor are they timely, in most
pediatric rheumatology centers.
In summary, we have developed a set of classi-
fication criteria for MAS complicating systemic JIA
and provided preliminary evidence of their validity.
These criteria will help standardize the design and con-
duct of future clinical trials and research studies and
contribute to enhancing knowledge and awareness of
the syndrome.
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